Biocon arm inks pact to launch biosimilar Bmab 1200 in multiple countries 0 29.08.2024 09:51 Business Standard The biopharmaceutical company said that its subsidiary, Biocon Biologics has secured market entry for its proposed biosimilar, Bmab 1200, which is designed to compete with Stelara, in Europe, the UK, Canada, and Japan. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
